
InnoCare announces first patient dosed in zurletrectinib clinical trial in China
Betsy Goodfellow | January 24, 2024 | News story | Research and Development | InnoCare, Oncology, clinical trial, zurletrectinib
InnoCare Pharma has announced that the first paediatric patient has been dosed in a clinical trial of the company’s second generation pan-TRK inhibitor zurletrectinib at Sun Yat-sen University cancer Center in China.
This marks the first time the drug has been assessed in a trial of paediatric (two to 12 years old) patients, although it has demonstrated positive safety and efficacy in adult and adolescent (12 to 18 years old) patients.
Zurletrectinib, is a pan-TRK inhibitor which hinders the activity of the wild type TRKA, TRKB and TRKC, as well as mutant TKRA with resistant mutations G595R or G667C.
The company intends to submit a new drug application in China during the second half of 2024.
Dr Jasmine, co-founder, chairwoman and chief executive officer of InnoCare, commented: “NTRK gene fusion is a driving factor for various adult and paediatric cancers. It is inspiring that we continue to make positive progress in our clinical research of zurletrectinib for patients of different ages with NTRK gene fusion. We expect to see our innovative assets benefit solid tumor patients in the near future.”
Betsy Goodfellow
Related Content

Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …

How will biomarker-led diagnostics reshape respiratory medicine?
By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed …





